Main ContentAdolescents Type 2 Diabetes
Study title
Phase 3, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of Exenatide once weekly in adolescents with type 2 diabetes
- Principal Investigator: Naznin Dixit
Purpose
This study seeks to evaluate the effect of an experimental drug in children and adolescents with type 2 diabetes mellitus.
Who can participate
Those eligible to participate in this study include:
- Adolescents ages 10-17 diagnosed with type 2 mellitus
For more information
- Deepali Bhatt
University of Mississippi Medical Center
2500 N. State St.
Jackson, MS 39216
(601) 815-9481 - IRB Number: 2017-0183